Illustration of researchers presenting funding support for SPG601 fragile X syndrome clinical trial backed by FRAXA

FRAXA Backs Upcoming Phase 2B Trial of SPG601 for Fragile X Syndrome

FRAXA Research Foundation is supporting a Phase 2b clinical trial of SPG601, an experimental therapy targeting BK channels in fragile X syndrome, following promising early results.

Read More »
Craig Erickson, MD (left) and Stella Sarraf, PhD (right) on a video call for the Spinogenix SPG601 Fragile X clinical trial.

Spinogenix and FRAXA Advance SPG601 Into Phase 2b Trial for Fragile X Syndrome

Spinogenix and FRAXA are supporting a Phase 2b clinical trial of SPG601 in Fragile X syndrome, building on Phase 2 signals and FDA designations.

Read More »

Categories

FRAXA Funded Research

Current Research Grants (37)